Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
JD Health International, Inc. ( (HK:6618) ) has provided an announcement.
JD Health International, Inc. announced its interim results for the first half of 2025, reporting significant financial growth with a 24.5% increase in revenue to RMB35.3 billion and a 27.4% rise in profit to RMB2.59 billion. The company has improved its healthcare offerings and advanced AI-enhanced service models, reinforcing its leading position in the healthcare market and addressing the growing demand for high-quality healthcare services. The company’s strategic focus on AI and health consumption aligns with China’s policies promoting high-quality healthcare development, further solidifying its market position.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$56.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International, Inc. operates in the healthcare industry, focusing on providing healthcare products and services. The company is known for its omnichannel model that includes direct sales, online marketplace, and on-demand retail, partnering with leading pharmaceutical companies to enhance service experiences and maintain competitive pricing.
Average Trading Volume: 8,992,967
Technical Sentiment Signal: Buy
Current Market Cap: HK$172.5B
Find detailed analytics on 6618 stock on TipRanks’ Stock Analysis page.